Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Arimoclomol
13 evidence topics · 14 sources
Guideline recommendation: arimoclomol for patients with neurological symptoms on background miglustat
“Arimoclomol is a small‐molecule drug classified as a heat shock protein co‐inducer, targeting HSP70, approved by the FDA in combination with miglustat for the treatment of NPC” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Statement #17: All patients with a confirmed diagnosis of NPC and neurological symptoms using background miglustat treatment should be considered for arimoclomol therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Expert's opinion: completely agree (37.93%), mostly agree (37.93%), partially agree (20.69%), partially disagree (3.45%), mostly disagree (0.00%), and completely disagree (0.00%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
U.S. regulatory history: complete response letter in June 2021
U.S. regulatory history: advisory committee vote in August 2024
U.S. approval in September 2024 in combination with miglustat
Phase 2/3 trial NPC-002: prespecified 5-domain NPCCSS primary endpoint
“In a 12‐month, prospective, randomised, double‐blind, placebo‐controlled, phase 2/3 trial (ClinicalTrials.gov identifier: NCT02612129), patients (2‐18 years) were randomised 2:1 to arimoclomol:placebo, stratified by miglustat use.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The primary endpoint was change in 5‐domain NPC Clinical Severity Scale (NPCCSS) score from baseline to 12 months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Fifty patients enrolled; 42 completed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At month 12, the mean progression from baseline in the 5‐domain NPCCSS was 0.76 with arimoclomol vs 2.15 with placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A statistically significant treatment difference in favour of arimoclomol of −1.40 (95% confidence interval: −2.76, −0.03; P = .046) was observed, corresponding to a 65% reduction in annual disease progression.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the prespecified subgroup of patients receiving miglustat as routine care, arimoclomol resulted in stabilisation of disease severity over 12 months with a treatment difference of −2.06 in favour of arimoclomol (P = .006).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Adverse events occurred in 30/34 patients (88.2%) receiving arimoclomol and 12/16 (75.0%) receiving placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Fewer patients had serious adverse events with arimoclomol (5/34, 14.7%) vs placebo (5/16, 31.3%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Treatment‐related serious adverse events (n = 2) included urticaria and angioedema.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Phase 2/3 trial NPC-002: rescored 4-domain NPCCSS introduced post hoc
“To more accurately assess changes in disease course over a 12-month time period in a heterogeneous group of patients, the Cognition domain was removed from the 5DNPCCSS and the Swallow domain was rescored to reflect linearity in disease progression.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The NPC-002 post-hoc primary analysis showed a mean standard error (SE) change in R4DNPCCSS score of 0.35 (0.40) with arimoclomol (N = 34) versus 2.05 (0.54) with placebo (N = 16), and a treatment effect in favor of arimoclomol over placebo of −1.70 (p = 0.0155).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the miglustat subgroup analysis, mean (SE) change in R4DNPCCSS score was −0.23 (1.02) with arimoclomol (N = 22) versus 1.92 (3.37) with placebo (N = 12), representing a treatment effect of −2.21 (p = 0.0077).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Phase 2/3 trial NPC-002: results in the miglustat subgroup in the prescribing information
| R4DNPCCSS score | MIPLYFFA with miglustat (N=26 at baseline, N=22 at month 12) | Placebo with miglustat (N=13 at baseline, N=12 at month 12) |
|---|---|---|
| Baseline, mean (SD) | “8.9 (6.1)” | “7 (5.8)” |
| Change from baseline to month 12, mean (SD) | “-0.2 (1)” | “1.9 (3.4)” |
| Change from baseline to month 12, LS mean (SE) | “-0.2 (0.5)” | “2 (0.7)” |
| Placebo-subtracted difference (95% CI) | “-2.2 (-3.8, -0.6)” | Not applicable |
Appraisal of the phase 2/3 trial in a state Medicaid drug evaluation
Long-term data: 48-month open-label extension of NPC-002
“Of the 50 patients who started the DB phase, 41 entered the OLE phase, with 29 completing 48 months.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“During the OLE, mean (SD) 5DNPCCS and R4DNPCCSS scores increased by 3.2 (4.8) and 2.7 (4.2) over 48 months, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Among patients switching from placebo to arimoclomol after the DB phase, mean annual change in 5DNPCCSS decreased from 2.0 (on placebo) to 0.1 in the first year of receiving arimoclomol and mean annual change in R4DNPCCSS decreased from 1.9 to 0.2, indicating slowing of disease progression.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The score pattern in the subset of patients who received miglustat as part of their standard care regime in addition to arimoclomol (N = 33) was similar to that seen in the total population.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Arimoclomol was well-tolerated over 48 months, with no new safety concerns identified.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Long-term data: U.S. early access program over 4 years
“Participants were enrolled at 14 US sites.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Among 109 participants, 53 (48.6%) were adults (≥18 years) and 71 (65.1%) received miglustat alongside arimoclomol.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Mean (SD) arimoclomol exposure was 820 (539) days.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Of 248 reported AEs, 17 events in 13 participants (12.8%) were treatment related.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“5DNPCCSS scores remained relatively stable throughout the program, with mean (SD) total scores of 11.0 (6.15) at Baseline (n = 100) and 12.0 (7.32) at Year 4 (n = 22).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Infants younger than 24 months: open-label pediatric substudy
“The dosing regimen used for patients <24 months differed from the regimen recommended in the FDA label.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Five patients (three females, two males; aged 14–23 months at screening) were enrolled; four remained in the study >12 months; arimoclomol exposure ranged from 72 to 1109 days.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All patients received concomitant miglustat.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Two AEs in one patient (elevated alanine/aspartate aminotransferases) were considered probably related to arimoclomol and resolved within 51 days; the patient was withdrawn from the substudy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Further investigation in larger cohorts is warranted to elucidate the impact of arimoclomol in NPC patients under 2 years of age.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote